Guidelines on the Use of Benzodiazepines and Related Medicine

Article excerpt

In accordance with the opinions of the Fellows of the Hong Kong College of Psychiatrists as expressed in the Annual General Meeting of the College in December 1995, the Council of the College set up an Ad Hoc Committee to draft its guidelines on the use of benzodiazepines and related medicine. Members of the Committee were Prof, C.N. Chen, Dr. Barry Connell, Dr. Benjamin Lai, Dr. S.P. Leung, and Dr. Y.K. Wing. References were made to the various documents. These included the Use of Benzodiazepines of the World Psychiatric Association. Guidelines on the Use of Benzodiazepines by the Royal College of Psychiatrists of the United Kingdom, and Guidelines on the Use of Benzodiazepines of New Zealand. Opinions and comments had also been received from various Fellows and Members of the College at various stages of development of the guidelines. Draft on the guidelines was discussed by the Council of the College and modified according to the views of the Council. The Guidelines was formally adopted by the College Council in March 1996 as presented below.

Benzodiazepines are useful and effective pharmacological agents when they are used for the right indications with treatment properly -supervised, dosage appropriate chosen and adjusted, and used for an appropriate period of time. They are used in the pharmacological aspect of the overall management of patients with anxiety and Insomnia. Some benzodiazepines are also used in other conditions, like in the use as an anti-epileptic agent and as a muscle relaxant. However they pose the risk of abuse, acute or chronic intoxication, and dependence in addition to the adverse effects of slowing of reaction time, impairment of memory, mood changes, and paradoxical effects of excitation and aggressiveness. The likelihood of dependence increases with increasing dose and increasing duration of treatment. Withdrawal symptoms have been reported with benzodiazepines following therapeutic doses given even for a short period of time. Short and intermediate half-life hypnotics, like triazolam and medazepam, are said to be more likely to lead to withdrawal symptoms. Dependence may also be more likely with a benzodiazepine of higher potency, like flunitrazepam.

Anxiety and insomnia are often symptoms of an underlying psychiatric illness. They often indicate the presence of psychosocial stresses affecting a patient who is having an underlying psychopathology. The management of the patient requires a proper and comprehensive psychiatric assessment and biopsychosocial management, The risks and benefits of treatment with benzodiazepines must be discussed with the patient. The progress of the patient must be reviewed regularly and the management adjusted appropriately


The following serves as guidelines of good clinical practice in the use of benzodiazepines as a pharmacological agent in the following uses.


Benzodiazepines are indicated as a pharmacological agent in the overall psychosocial management of a patient with anxiety that is severe, disabling or subjecting the individual to unacceptable distress. The anxiety may occur alone or in association with insomnia or short-term psychosomatic, organic or psychotic illnesses. The use of the agent should in general be for short term use.


Benzodiazepines should be used as a pharmacological agent in the overall management of a patient with insomnia only when it is severe, disabling or subjecting the individual to extreme distress. …


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.